A Randomized, Double-Masked, Vehicle-Controlled Proof-Of-Concept Study for Topically Delivered LHA510 as a Maintenance Therapy in Patients With Wet Age-Related Macular Degeneration (AMD)
Phase of Trial: Phase II
Latest Information Update: 13 Jan 2017
At a glance
- Drugs LHA 510 (Primary) ; Ranibizumab
- Indications Wet age-related macular degeneration
- Focus Proof of concept; Therapeutic Use
- Sponsors Alcon
- 24 Oct 2016 Status changed from active, no longer recruiting to completed.
- 15 Aug 2016 Planned End Date changed from 1 Sep 2016 to 1 Oct 2016.
- 15 Aug 2016 Planned primary completion date changed from 1 Sep 2016 to 1 Oct 2016.